Interview Atox Aims For Reltecimod OK In 2020
Interview: Atox Aims For Reltecimod OK In 2020
08:27 EDT 24 Jul 2019 |
SCRIP
The Israeli biotech is eagerly awaiting Phase III data on its therapy for necrotizing soft tissue infections before the end...
Original Article: Interview: Atox Aims For Reltecimod OK In 2020
More From BioPortfolio on "Interview: Atox Aims For Reltecimod OK In 2020"